{"prompt": "['21', 'of nitric oxide synthase (NOS) levels, leading to small vascular vasoconstriction, larger vascular', 'calcifications and constriction, which ultimately result in nerve ischemia. 6,7,8', 'Therapeutic intervention for the prevention and treatment of DSPN includes optimized glycemic', 'control, dietary and lifestyle based counselling, antioxidant-rich nutrition, weight management,', 'moderate exercise, routine foot screening, proper foot wear, and avoidance of alcohol and tobacco.', 'Other than tight glycemic control, there are no effective treatments that target the pathophysiology', 'of DSPN. In addition to glycemic control, diabetic neuropathy management has focused', 'predominantly on symptomatic pharmaceutical pain control with analgesics and medications such', 'as pregabalin and duloxetine (FDA approved for the treatment of neuropathic pain from diabetes). 3', 'Pharmacologic agents prescribed for pain from DSPN are listed in Table 3.', 'Table 3. Pharmacologic interventions for the treatment of pain associated', 'with DSPN 3,4', 'Drug Class', 'Agent', 'Effective Dose', 'Anticonvulsants', 'Pregabalin', '300-600 mg/day', 'Gabapentin', '900-3,600 mg/day', 'Antidepressants (Serotonin-', 'Duloxetine', '60-120 mg/day', 'norepinephrine reuptake inhibitors)', 'Venlafaxine', '75-225 mg/day', 'Amitriptyline', '25-100 mg/day', 'Tricyclic antidepressants (TCA)', 'Desipramine', 'Nortriptyline', '210 mg/day', 'Immediate Release:', 'Tramadol', 'Opioids', 'day 1: 700mg; day 2', 'Tapentadol', '60 mg/day', 'Extended Release: 50', 'mg, twice daily', '* Adapted from Pop-Busui, R, Boulton, AJ. Diabetic Neuropathy: A Position Statement by the American', 'Diabetes Association. Diabetes Care 2017 Jan; 40(1):141-142 3', 'While TCAs are the most studied agents used for neuropathic pain, the use of such agents has', 'occurred in the absence of regulatory approval from the Food and Drug Administration (FDA).', 'Duloxetine (CymbaltaR) and pregabalin (LyricaR) are medications approved by the FDA', 'specifically for the treatment of painful peripheral diabetic neuropathy. Patients may supplement', 'oral agents with topical therapy- including capsaicin 0.075% cream, doxepin 5% solution or', 'lidocaine 5% patches. Additionally, topical nitrates, alpha-lipoic acid antioxidant, and homeopathic', 'agents such as evening primrose oil have been reported with variable success in reducing', 'neuropathic pain. Opioids are generally prescribed for severe, unresponsive pain.', 'In an effort to avoid overuse of opioids for severe unrelenting pain, the American Pain Society and', 'the Academy of Pain Medicine have generated guidelines that include the use of non-', 'pharmaceutical interventions currently used to treat chronic pain, Clinical Guidelines for the Use', 'of Chronic Opioid Therapy in Chronic Noncancer Pain. Non-pharmaceutical agents such as', 'electrical nerve stimulation (E-Stim), acupuncture, electro-acupuncture, cognitive behavioral', '710-7105-01', 'RBI.2017.002 Version C', 'CONFIDENTIAL']['22', 'therapy (CBT), biofeedback, and physical therapy (PT) have some usefulness in treating painful', 'peripheral DSPN. 11', 'Potential Therapeutic Value of Pulsed Electromagnetic Energy Fields (PEMF) for DSPN', 'Provant R Therapy System is a medical device manufactured by Regenesis Biomedical, Inc.', '(Scottsdale, AZ), that has been cleared by the FDA (K972093, K091791, AND K131979) \"for', 'adjunctive use in the palliative treatment of post-operative pain and edema in superficial soft', 'tissue.\" The device delivers self-administered, non-thermal, non-ionizing pulsed electromagnetic', 'energy to the target tissue, using 27.12 MHz pulses lasting 42 microseconds and delivered 1000', 'times per second. The system generates an electromagnetic field that is continuously monitored', \"and regulated to ensure consistent dosing. Life Science laboratory research led to Provant Therapy's\", 'energetic settings, which have been associated with reductions in post-operative chronic pain in a', 'clinical trial. Provant Therapy is dual-field electromagnetic energy (i.e. high electric and magnetic', 'fields). High energy electric and magnetic fields in combination have been associated with changes', 'in gene expression which are involved in pain and inflammation pathways in laboratory studies. 23,32', 'The therapeutic electromagnetic field is delivered by means of an applicator pad that is placed', 'against the treatment site. The device is non-invasive and does not require placement of surface or', 'deep electrodes, nor removal of bandages or clothing. Treatment is usually imperceptible and very', 'well tolerated. Evidence suggests that the Provant Therapy System can reduce pain, promote', 'healing, and promote restored range of motion following reparative surgery in wounded', 'extremities. 19,21 As an analgesic, it is non-addictive and does not alter the mental state of the user.', 'Regenesis Biomedical, Inc., has marketed the device since 2004 and has treated over 15,000', 'patients within the U.S. Over two million individual treatments have been administered with rare', 'adverse events reported. 15 In addition, the safety of PEMF has been well documented. The 2012', 'meta-analysis by Guo et al20 of 25 clinical trials of PEMF in the treatment of pain, edema and', 'wound healing identified no serious adverse events among 1,332 patients treated with PEMF. In', 'addition, the same meta-analysis found statistically significant evidence supporting the efficacy of', 'adjunctive PEMF therapy for pain relief, edema reduction, and wound healing promotion. Finally,', 'adjunctive PEMF therapy has been reported effective in alleviating pain resulting from', 'trauma,', '12,14,16,23,25,27 and chronic pain. 13,15,26', 'In vitro and in vivo evidence suggest PEMF functions by modulating factors involved in pain', 'signaling and soft tissue repair. In vitro studies demonstrated that PEMF treatment of cells in culture', 'can mediate wide-spread changes in transcript levels encoding factors involved in pain and the', 'inflammatory response (including endogenous opioids, growth factors, cytokines, and cell cycle', 'regulating factors), 20,21,24 and can promote cell proliferation. 17 Regenesis Biomedical, Inc. scientists', 'recently found that PEMF increases endogenous opioid expression, which coincides with an', 'increase in endothelin receptor B in keratinocytes, suggesting that PEMF treatment induces a', 'localized analgesic effect by activation of these receptors by endothelin-1 21,22', 'These findings have', 'led to the proposition that PEMF activates peripheral endogenous opioids which, in turn, activate', 'an analgesic cascade via the endothelin pain axis. In a recent clinical study, PEMF usage for post-', '710-7105-01 C', 'RBI.2017.002 Version C', 'CONFIDENTIAL']\n\n###\n\n", "completion": "END"}